![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.00 | 15.50 | 16.50 | 16.00 | 16.00 | 16.00 | 38,250 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 5.63 | 14.59M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/10/2016 14:13 | added at 62.4p - too good an opportunity to miss IMV | ![]() bdog51 | |
26/10/2016 14:07 | In fact elrico that's the whole point. Opti will keep having to stump up cash for product development, launches and marketing etc. That's why they are so keen to hive off parts of the company in IPOs. | ![]() michaelmouse | |
26/10/2016 14:05 | Someuwin, excellent email response thank you. | ![]() john henry | |
26/10/2016 14:04 | "JV funding dear." Indeed elrico. Opti's contribution to SkinBiotix (so far)for ONE product development was £400,000. | ![]() michaelmouse | |
26/10/2016 14:04 | SOH email is nothing more than a translation service for people that seem incapable of reading RNs. Today's update covered the cholesterol & hypertension routes to commercial reality and offered scope on timing. It also suggested there are not just multiple partners, but multiple routes to market and multiple platforms. In laymen terms for the usual suspect....more revenue sources on a global scale. It also highlighted we are much closer than even the bullish of bulls thought. It also confirmed our first product is already profitable. Of course some can't see the mountain in from of you because you're too close to it. | elrico | |
26/10/2016 14:00 | JV funding dear. Have you learned nothing of OPTI strategy in all this time! | elrico | |
26/10/2016 13:58 | "From point 6, final sentence, he says cash is still the same as reported in the interims." Well done Lukead. That is the piece of price sensitive information. However, it got me thinking. Why didn't he say that in the RNS? It's because of what he said (reproduced) above. The deals will be a right old mix and will need substantially more funding from Opti since they will be stumping up for product development, launches and marketing. This will require multi-millions to generate significant revenues and, in a few years time if they're lucky, profits. That statement changes nothing (if true?). Far more funding is needed. SP may bounce around a little at the round numbers i.e. 60p, 50p then on to 40p. In summary it just adds further confirmation to my thoughts, otherwise the RNS would have said something to the effect that the cash position is strong and the company anticipates that no further funding is necessary. | ![]() michaelmouse | |
26/10/2016 13:57 | Michaelmouse - you really don't need to demonstrate your lack of knowledge. It's not beyond doubt. SOH email is nothing more than a translation service for people like you that seem incapable of reading RNs. Today's update covered the cholesterol & hypertension routes to commercial reality and offered scope on timing. It also suggested there are not just multiple partners, but multiple routes to market and multiple platforms. In laymen terms....more revenue sources on a global scale. It also highlighted we are much closer than even the bullish of bulls thought. It also confirmed our first product is already profitable. Of course you can't see the mountain in from of you because you're too close to it. | elrico | |
26/10/2016 13:56 | I do think that the ' clown ' M'Mouse on the other thread that he had set up, should be reported to Advfn police. He has been scaremongering on that thread with made up lies. He is a total nuisance and thinks even that email from SOH is made up. He is only here because of vengeance, being neither long or short. I don't see why he is allowed to post on this bulletin board. | ![]() lukead | |
26/10/2016 13:55 | someuwin, My thanks also for getting that update from SOH. It is indeed a shame that RNS's have to have such 'stilted' content. Bestwishes - Mike | ![]() spike_1 | |
26/10/2016 13:46 | Nice one, Parob ! | ![]() dogwalker | |
26/10/2016 13:38 | Thanks someuwin, excellent update from SOH. Will be adding. | ![]() rafboy | |
26/10/2016 13:37 | Thank you someuwin. From point 6, final sentence, he says cash is still the same as reported in the interims. That should be of particular interest to the 'clown ' on other thread, for he reckoned that it was much lower, hence the need of further placings. His scaremongering wont be as now, on that knowledge. Ps he even used one of your postings as ammunition to help his cause. | ![]() lukead | |
26/10/2016 13:34 | Added a few more myself. | ![]() someuwin | |
26/10/2016 13:33 | Well we did hit 60p on the bid earlier, so monkeywench was right there. Next stop £1 then!!! | ![]() parob | |
26/10/2016 13:33 | If the e-mail posted on the main thread is genuine then it's a flagrant breach of market rules. Have you all spotted the price sensitive information? This is not the first time either. Bargepole stuff. It also confirms my previous post:- "Groups experienced in this area will appreciate that whilst its easier to give rights to one group you then lose control and have a dependence on that company. AIM is littered with companies who have struck early commercial deals with big partners who then lost interest and then have nowhere to go. Whilst painful and timeconsuming as the RNS states multiple deals diversifies investor risk and if successful will give a greater shareholder return." There is NO major deal just around the corner. | ![]() michaelmouse | |
26/10/2016 13:28 | Well thats my very last TU | ![]() judijudi | |
26/10/2016 13:26 | There is clearly disappointment in the market that yet another RNS has happened along that fails to deliver a killer blow. There are clearly positive dimensions to this RNS - firstly, the cholesterol focus (of which we had heard little in recent times) is on track, gaining momentum all the while, and we'll get an up-date in November, poised, in turn, for a product launch in Spring 2017. Cardiovascular initiatives that work, surely rank as eye-catching investment opportunities. Secondly, to-days RNS deals exclusively with the cardiovascular dimension to OPTI - nothing whatever to do with developments related to Skinbiotox and Sweebiotics and their planned segregation. Nothing we can do about market forces - even if they were to depress share-price to 40p as some suggest. But what has this got to do with the many innovative lifestyle propositions on the OPTI agenda? Maybe SOH could work a bit harder to re-assure his patient loyal PIs; or maybe not - he has better things to focus on! | owenmo | |
26/10/2016 13:24 | may not be the bottom, but im buying anyway | ![]() currypasty | |
26/10/2016 13:23 | Thank you, someuwin. Pity RNS's can't be as plain-speaking & clear as SOH is himself. | ![]() dogwalker | |
26/10/2016 13:15 | Cheers Parob I think everyone's just frustrated that the share price keeps falling regardless of news. I will not sell at these prices and intend to hold for another two years. Just bought a long term SB position today rather than paying full price for now. Onwards and upwards - hopefully! EDIT and you too someuwin - guess it's just a case of waiting | ![]() whl2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions